Performance Overview - The company reported a revenue of 308 million yuan for 2025, representing a year-on-year growth of 65.26%. The net profit reached 15.1578 million yuan, showing a significant increase of 153.62% [1] Company Status - On January 9, 2026, the company announced an employee stock ownership plan draft involving 48 core employees, with a lock-up period of 14 months. The performance assessment targets include a sales volume or net profit growth rate of no less than 12% for 2026. The implementation and its impact on team stability will be worth monitoring [2] Funding Dynamics - The fourth extraordinary general meeting of shareholders approved the bank credit limit for 2026, with the resolution announced on January 6, 2026. Attention should be paid to whether the actual allocation of funds supports business expansion or technological upgrades [3] Business Progress - Following the acquisition of Intricon's hearing health business in 2024, the sales revenue from hearing aid chips reached approximately 20 million yuan in 2025, showing significant year-on-year growth. The demand for OTC hearing aids in the U.S. continues to rise amid global aging trends, and future focus may be on technology integration and omnichannel operations [4]

Group 1 - The core point of the article is that Jinhao Medical (920925) reported a significant increase in net profit for 2025, with a growth rate of 153.62% compared to the previous year [1][2] - As of February 9, 2026, Jinhao Medical's stock closed at 22.73 yuan, reflecting a 0.71% increase with a trading volume of 12,600 shares and a total transaction amount of 28.57 million yuan [1] - On February 9, the main capital inflow was 2.7391 million yuan, accounting for 9.59% of the total transaction amount, while retail investors saw a net inflow of 346,400 yuan, representing 1.21% of the total [1][2] Group 2 - The company is set to release its annual report for 2025, which is anticipated to confirm the reported net profit of 0.0152 billion yuan [1][2]

Core Viewpoint - The company reported significant growth in both revenue and profit for the year 2025 compared to the previous year, indicating strong financial performance and operational efficiency [1]. Financial Performance - The company's operating revenue for 2025 reached 308 million yuan, up from 186 million yuan in the previous year, representing a year-on-year increase of 65.26% [1]. - The total profit amounted to 17.56 million yuan, compared to 4.75 million yuan in the prior year, reflecting a substantial year-on-year increase of 270.03% [1]. - The net profit attributable to shareholders was 15.16 million yuan, an increase from 5.98 million yuan in the previous year, marking a year-on-year growth of 153.62% [1].

Group 1 - The core point of the article is that JinHao Medical has announced a restricted stock incentive plan aimed at motivating key personnel, with specific performance targets set for revenue and net profit [1] Group 2 - As of February 4, 2026, JinHao Medical's stock closed at 22.7 yuan, with a market capitalization of 2.235 billion yuan [1] - The stock opened at 22.75 yuan, reached a high of 22.9 yuan, and a low of 22.62 yuan, with a trading volume of 25.5143 million yuan and a turnover rate of 2.03% [1] - The company plans to grant 200,000 shares of restricted stock to three incentive targets at a price of 8.77 yuan per share, with a lock-up period of 12 to 24 months [1] - The performance targets for the company include achieving a minimum revenue of 300 million yuan in 2026 or a cumulative net profit of 55 million yuan over three years, and a minimum revenue of 350 million yuan in 2027 or a cumulative net profit of 90 million yuan over three years [1]

Core Viewpoint - The company, Jinhao Medical, is expected to see significant profit growth in 2025, driven by increased demand in the US OTC hearing aid market and strategic partnerships [1] Financial Performance - As of January 27, 2026, Jinhao Medical's stock closed at 23.75 yuan, down 3.46% from the previous trading day, with a total market capitalization of 2.338 billion yuan [1] - The company anticipates a net profit attributable to shareholders of 15 million to 16 million yuan for 2025, representing a growth of 150.98% to 167.72% compared to the previous year's profit of 597.65 million yuan [1] Business Strategy - The growth in performance is attributed to the rising demand in the US OTC hearing aid market, enhanced collaboration with brand partners, and the promotion of its own brand through a full-channel operation [1] - The acquisition of Intricon's hearing health business is expected to contribute approximately 20 million yuan in hearing aid chip sales revenue, an increase of about 16.5 million yuan year-on-year [1]

Core Viewpoint - The company expects a net profit attributable to shareholders of 15 million to 16 million yuan for the full year of 2025, driven by growth in the OTC hearing aid market and successful integration of acquired technology [1] Group 1: Performance Forecast - The company anticipates a year-on-year increase in net profit attributable to shareholders for 2025, primarily due to sustained demand in the U.S. OTC market and enhanced operational strategies [1] - The company has strengthened partnerships with key brand clients, leading to increased orders and revenue from brand partners [1] - The company has accelerated the development of its own brand channels, resulting in significant revenue growth from proprietary products [1] Group 2: Recent Financial Results - For the first three quarters of 2025, the company reported a main operating revenue of 196 million yuan, an increase of 82.44% year-on-year [2] - The net profit attributable to shareholders for the same period reached approximately 17.63 million yuan, reflecting a year-on-year increase of 565.54% [2] - The third quarter alone saw a main operating revenue of 82.22 million yuan, up 87.17% year-on-year, with a net profit of approximately 991.96 thousand yuan, marking a staggering increase of 1162.04% [2]

Group 1 - The stock price of Jinhai Medical (920925) closed at 24.79 yuan on January 19, 2026, with a slight increase of 0.08% and a turnover rate of 2.99% [1] - The trading volume was 16,500 shares, with a total transaction amount of 40.9653 million yuan [1] - On January 19, the main funds experienced a net outflow of 2.5742 million yuan, accounting for 6.28% of the total transaction amount, while retail investors had a net inflow of 115,500 yuan, representing 0.28% of the total [1][3] Group 2 - Jinhai Medical announced the internal public notice of the list of incentive objects for the 2025 restricted stock incentive plan from January 6 to January 16, 2026, with no objections from employees during the public notice period [1] - The independent directors confirmed that the incentive objects meet the relevant legal regulations and the conditions specified in the draft of the 2025 restricted stock incentive plan, and they are qualified for the position [1] - The incentive objects include senior management and core employees of the company and its subsidiaries, excluding independent directors and foreign employees [1]

Core Viewpoint - Jinhai Medical (920925) has announced the internal public notice of the incentive object list for the 2025 restricted stock incentive plan, which has received no objections from employees during the public notice period [1] Group 1: Stock Performance - As of January 19, 2026, Jinhai Medical's stock closed at 24.79 yuan, up 0.08% from the previous trading day, with a total market capitalization of 2.441 billion yuan [1] - The stock opened at 24.92 yuan, reached a high of 24.92 yuan, and a low of 24.66 yuan, with a trading volume of 40.9653 million yuan and a turnover rate of 2.99% [1] Group 2: Incentive Plan Announcement - The company announced that from January 6 to January 16, 2026, it conducted an internal public notice regarding the incentive object list for the 2025 restricted stock incentive plan [1] - The independent directors held a special meeting and concluded that the selected incentive objects meet the relevant legal regulations and the conditions set forth in the draft of the 2025 restricted stock incentive plan, confirming their qualifications [1] - The incentive objects include senior management and core employees of the company and its subsidiaries, excluding independent directors and foreign employees [1]

Core Viewpoint - The company JinHao Medical has reported an increase in stock price and provided updates on the use of idle funds for purchasing financial products, indicating a strategic approach to asset management [1]. Group 1: Stock Performance - As of January 13, 2026, JinHao Medical's stock closed at 26.66 yuan, up 1.21% from the previous trading day [1]. - The stock opened at 26.6 yuan, reached a high of 27.5 yuan, and a low of 26.2 yuan, with a trading volume of 2.4 billion yuan and a turnover rate of 16.12% [1]. Group 2: Financial Product Investment - The company announced the use of up to 100 million yuan of idle self-owned funds to purchase low-risk, high-liquidity bank financial products, approved by the board on October 27, 2025 [1]. - As of January 13, 2026, the remaining balance of the purchased financial products was 60.2 million yuan, representing 16.92% of the company's audited net assets as of the end of 2024 [1]. - The company has added a purchase of 10 million yuan in structured deposits from the Bank of China, with a term of 119 days and an expected annual yield of 0.6% or 1.9%, funded by self-owned capital [1].

Group 1 - Jinhai Medical (920925) experienced a decline of 14.76% today, with a turnover rate of 32.59% and a transaction volume of 517 million yuan, showing a fluctuation of 14.83% [2][3] - The stock was listed on the daily turnover board due to its turnover rate reaching 32.59%, with a net selling amount of 158 million yuan from brokerage seats [3] - The top five brokerage seats accounted for a total transaction volume of 224 million yuan, with a buying amount of 33.13 million yuan and a selling amount of 191 million yuan, resulting in a net selling of 158 million yuan [3] Group 2 - The largest buying brokerage was Dongfang Caifu Securities, Lhasa Tuanjie Road First Securities, with a buying amount of 6.9757 million yuan, while the largest selling brokerage was Guotai Haitong Securities, Chongqing Jiefangbei, with a selling amount of 58.6743 million yuan [3] - Detailed trading information shows that multiple brokerage seats from Dongfang Caifu Securities were involved in buying, with significant amounts also sold by other brokerages [3]